Arbutus Biopharma (ABUS) Total Current Liabilities (2010 - 2026)

Arbutus Biopharma has disclosed Total Current Liabilities across 17 years of filings, most recently posting $5.1 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $5.1 million, down 73.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.1 million (down 73.73% YoY), and the FY2025 annual result was $6.0 million, down 61.54% from the prior year.
• Total Current Liabilities came in at $5.1 million for Q1 2026 at Arbutus Biopharma, down from $6.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $32.9 million in Q4 2022 to a low of $5.0 million in Q2 2025.
• The 5-year median for Total Current Liabilities is $22.3 million (2023), against an average of $19.7 million.
• Across the five-year window, Total Current Liabilities soared 384.22% in 2022 and slumped 77.77% in 2025, its largest moves.
• Arbutus Biopharma's Total Current Liabilities stood at $32.9 million in 2022, then plunged by 31.56% to $22.5 million in 2023, then plunged by 30.55% to $15.6 million in 2024, then plunged by 61.54% to $6.0 million in 2025, then fell by 15.0% to $5.1 million in 2026.
• The last three Total Current Liabilities figures came in at $5.1 million (Q1 2026), $6.0 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.